Press Enter to search · Esc to close
A 2025 analysis of 911 effect sizes asked which of longevity medicine's two favorite molecules truly mirrors dietary restriction. The answer reshuffles the conversation — carefully.
A cheap, decades-old drug is being reframed as a possible geroprotective adjuvant. The science is intriguing — and still unfinished.
A careful re-analysis of the Women's Health Initiative finds metformin initiators outlived sulfonylurea initiators on the way to age 90. It sharpens the longevity debate without ending it.